Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Uniquity Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Blackstone Launches Uniquity Bio For Novel Immunology And Inflammation Medicines
Details : MK-8226 (solrikitug), is a highly potent anti-TSLP monoclonal antibody, which is being evaluated in early-stage clinical trial for the treatment of chronic obstructive pulmonary disease and asthma.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 15, 2024
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Uniquity Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Uniquity Bio
Deal Size : $300.0 million
Deal Type : Financing
Blackstone Unsheathes Uniquity Bio with $300M
Details : The financing aims to fund the clinical development of MK-8226 (solrikitug), which is being evaluated in the early-stage clinical trial for chronic obstructive pulmonary disease and asthma.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
May 15, 2024
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Uniquity Bio
Deal Size : $300.0 million
Deal Type : Financing
Lead Product(s) : Seasonal Influenza Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Moderna Therapeutics
Deal Size : $750.0 million
Deal Type : Financing
Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program
Details : Proceeds will fund Moderna's influenza program, including mRNA-1010, a quadrivalent flu vaccine encoding hemagglutinin (HA) glycoproteins for four strains, administered intramuscularly.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : Seasonal Influenza Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Moderna Therapeutics
Deal Size : $750.0 million
Deal Type : Financing
Lead Product(s) : 24-Valent Pneumococcal Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Sutro Biopharma
Deal Size : $390.0 million
Deal Type : Collaboration
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration
Details : The financing will be used for the continued pipeline advancement and further development of its cell-free protein synthesis and site-specific conjugation technologies, including VAX-24, a Phase 3 ready, 24-valent next-generation pneumococcal conjugate v...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : $140.0 million
June 26, 2023
Lead Product(s) : 24-Valent Pneumococcal Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Sutro Biopharma
Deal Size : $390.0 million
Deal Type : Collaboration
Lead Product(s) : Migalastat
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Amicus Therapeutics
Deal Size : $30.0 million
Deal Type : Financing
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Details : The proceeds will be used to fund the ongoing operations of the company, including Galafold (migalastat), a small molecule and the first and only oral therapy for adults with Fabry disease and an amenable GLA variant.
Product Name : Galafold
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 10, 2023
Lead Product(s) : Migalastat
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Amicus Therapeutics
Deal Size : $30.0 million
Deal Type : Financing
Lead Product(s) : Ataluren
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : PTC Therapeutics
Deal Size : $50.0 million
Deal Type : Collaboration
Details : The strategic financing will support the acceleration of PTC’s robust and diversified pipeline having lead asset Translarna (ataluren), business development opportunities and general corporate purposes.
Product Name : Translarna
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 27, 2022
Lead Product(s) : Ataluren
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : PTC Therapeutics
Deal Size : $50.0 million
Deal Type : Collaboration
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Ferring Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Ferring Pharmaceuticals and Blackstone Life Sciences Restructure Novel Gene Therapy Collaboration
Details : The restructured agreement allows for a return on capital already invested by Blackstone, and also provides Blackstone with option to make a passive financial investment in nadofaragene firadonavec (rAd-IFN/Syn3) upon achievement of a specified regulator...
Product Name : Adstiladrin
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 17, 2022
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Ferring Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Isatuximab,Dexamethasone,Pomalidomide
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Sanofi
Deal Size : $330.0 million
Deal Type : Collaboration
Details : For the Sarclisa® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company to advance the development of a subcutaneous delivery for Sarclisa® with the goal of offering a unique patient-centric treatment e...
Product Name : Sarclisa
Product Type : Antibody
Upfront Cash : Undisclosed
March 15, 2022
Lead Product(s) : Isatuximab,Dexamethasone,Pomalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Sanofi
Deal Size : $330.0 million
Deal Type : Collaboration
Lead Product(s) : Obecabtagene Autoleucel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Autolus Therapeutics
Deal Size : $250.0 million
Deal Type : Acquisition
Details : Obecabtagene Autoleucel (Obe-cel) is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies used in adult ALL and B-NHL.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 11, 2021
Lead Product(s) : Obecabtagene Autoleucel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Autolus Therapeutics
Deal Size : $250.0 million
Deal Type : Acquisition
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Medtronic Plc
Deal Size : $337.0 million
Deal Type : Funding
Details : Funding will support Medtronic's Diabetes R&D, including a series of near-term programs such as the MiniMed™ 780G insulin pump system, its Personalized Closed Loop (PCL) system, extended wear infusion set, and Zeus and Synergy sensors.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
December 06, 2020
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Medtronic Plc
Deal Size : $337.0 million
Deal Type : Funding